Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of “Moderate Buy” from Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $59.5625.

Several analysts have weighed in on RARE shares. Cantor Fitzgerald boosted their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st. Guggenheim decreased their target price on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Barclays dropped their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. This trade represents a 17.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $24.90, for a total transaction of $116,606.70. Following the sale, the chief financial officer directly owned 110,342 shares in the company, valued at $2,747,515.80. The trade was a 4.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 24,002 shares of company stock valued at $575,039 over the last quarter. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RARE. Assenagon Asset Management S.A. lifted its position in Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after acquiring an additional 2,057,951 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares during the last quarter. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth $29,004,000. Eagle Health Investments LP purchased a new position in shares of Ultragenyx Pharmaceutical in the first quarter worth $18,522,000. Finally, Millennium Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 787.6% in the fourth quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock worth $20,255,000 after purchasing an additional 781,431 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $26.91 on Thursday. The firm’s fifty day moving average price is $24.17 and its 200-day moving average price is $24.91. The stock has a market cap of $2.65 billion, a P/E ratio of -4.40 and a beta of 0.37. Ultragenyx Pharmaceutical has a fifty-two week low of $18.29 and a fifty-two week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The firm had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.57) earnings per share. On average, analysts predict that Ultragenyx Pharmaceutical will post -4.53 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.